# HERTHENA-Breast04: what clinicians are saying

> 27 statements from 5 sources (1 video, 4 posts), 13 of them from 4 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026.

## Report

- Trial: An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04).
- NCT ID: NCT07060807
- Registry: https://clinicaltrials.gov/study/NCT07060807
- Sponsor: Merck Sharp & Dohme LLC
- Phase: Phase 3
- Status: Recruiting
- Drugs tested: patritumab deruxtecan
- Indication: hormone receptor-positive, HER2-negative unresectable locally advanced or metastatic breast cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-11-19 UTC
- Last checked: 2026-11-19 UTC
- Release hash: 637ebb1e5136d9b2756d6ceca3c5ed86c880f1c16c7f8ad82b276d3da55bd06e

## Counts

- Commentary sources screened: 28
- Sources cited by verified statements: 5
- Verified statements: 27
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 13
- Findings: 6
- Named people in screened sources (unnamed speakers and accounts not counted): 5
- Speakers cited: 5
- Cited speakers with a verified identity: 5
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 4
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 4
- By role and specialty (the abstract's specialty counts):
  - 2 physician, Medical oncology
  - 1 physician, specialty not confirmed
  - 1 physician, Hematology and oncology
- Organisational or shared accounts (not counted as people): 1

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

A medical oncologist viewed HERTHENA-Breast04 as a test of an ICARUS-B01 signal they considered comparable to T-DXd; that comparison rested on single-arm evidence. Commentary on the trial itself is limited. In the broader post-CDK4/6 discussion, a hematology-oncology physician would defer capecitabine or sacituzumab in a case they did not consider endocrine resistant. The sources reviewed for this edition contain no publication reporting the trial’s outcomes.

## Findings (titles)

- F2. Entry: a speaker sees possible access & contribution, no assured survival
  - 5 statements in 1 source, a podcast or video.
  - No named speaker is counted in this finding: its title's view comes from speakers the source does not name.
  - No named clinician · accounts and unnamed speakers.

### Beyond the trial population

- F1. HERTHENA-Breast04: why a clinician sees it as confirmatory after ICARUS-B01
  - 1 statement from 1 speaker in 1 source.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 4 cited clinicians.
- F3. Endocrine-sensitive case: a clinician defers chemo but excludes Trastuzumab deruxtecan
  - 7 statements from 1 speaker in 3 sources, 1 of them a podcast or video.
  - The one named speaker in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “exclude Trastuzumab deruxtecan”.
  - 1 of the report's 4 cited clinicians.
- F4. 1L progression: what speakers say
  - 3 statements from 1 speaker in 2 sources.
  - 1 of the report's 4 cited clinicians.
- F5. Second line: a clinician sees options, no known order; one queries prognosis
  - 8 statements from 3 speakers in 2 sources.
  - 1 of the 3 named speakers in this finding holds this view, a confirmed clinician; 1 of the 3 holds its caveat, “one queries prognosis”.
  - 3 of the report's 4 cited clinicians.
- F6. ICARUS-BREAST01: what a speaker highlights in the translational work
  - 2 statements from 1 speaker in 1 source.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.

5 of the 6 findings and 20 of the 27 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F2 | 5 | 1 | 1 | 0 | 3 |
| F1 | 1 | 2 | 1 | 1 | 2 |
| F3 | 7 | 9 | 3 | 1 | 3 |
| F4 | 3 | 3 | 2 | 1 | 2 |
| F5 | 8 | 8 | 2 | 3 | 3 |
| F6 | 2 | 2 | 1 | 1 | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F2 | 1 | 0 | 0 | 0 | 4 | 5 | 5 | 1 podcast or video |
| F1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 post or article |
| F3 | 4 | 0 | 0 | 0 | 3 | 7 | 6 | 2 posts and articles, 1 podcast or video |
| F4 | 2 | 0 | 0 | 1 | 0 | 3 | 0 | 2 posts and articles |
| F5 | 3 | 3 | 0 | 0 | 2 | 8 | 2 | 2 posts and articles |
| F6 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 1 post or article |

### Trial dimensions

- Primary endpoint: Progression Free Survival (PFS): F2 (2 shared claims)
- Primary endpoint: Overall Survival (OS): F2 (2 shared claims)
- Secondary endpoints: F2 (1 shared claims)
- Population and setting: F2 (2 shared claims)
- The comparison: F2 (1 shared claims)
- Safety and tolerability: F2 (2 shared claims)
- Design and conduct: no finding draws on it directly

## Abbreviations

- ADC: antibody–drug conjugate
- HCP: healthcare professional
- HER2: human epidermal growth factor receptor 2
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- OS: overall survival
- PFS: progression-free survival
- T-DXd: trastuzumab deruxtecan

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 27 | Paid |
| Who said each statement: the cited speakers | 5 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 4 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 5 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 12 | Free |
| Sources with links | 5 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 4 of the 5 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

11 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression Free Survival (PFS) | discussed | 2 | 1 |
| Primary endpoint: Overall Survival (OS) | discussed | 2 | 1 |
| Secondary endpoints | discussed | 1 | 1 |
| Population and setting | discussed | 2 | 1 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 2 | 2 |
| Safety and tolerability | discussed | 2 | 1 |
| Design and conduct | no commentary found | 0 | 0 |
| Endocrine-treatment boundary and the case-specific IHC 0 ADC judgment | discussed | 6 | 2 |
| Molecular work-up at progression | discussed | 3 | 2 |
| Second-line options, sequencing and the prognosis question after early progression | discussed | 7 | 2 |
| Earlier HER3-DXd evidence informing phase 3 expectations | discussed | 3 | 2 |
| Participation, possible access and patient communication | discussed | 2 | 1 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 5 statements · 19%** | | | |
| YouTube | 5 | 1 | 1 |
| **Posts · 22 statements · 81%** | | | |
| X threads | 14 | 3 | 20 |
| Bluesky threads | 8 | 1 | 7 |

- Screened window: 2025-08-27 to 2026-10-23
- Cited window: 2025-09-04 to 2026-02-11
- Retrieved: 2026-11-19

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04).
- Registry: NCT07060807 (https://clinicaltrials.gov/study/NCT07060807)
- Study IDs: 1022-016 · U1111-1317-5490 (UTN) · 2025-520582-51-00 (EU CT) · jRCT2031250297 (Japan Registry of Clinical Trial (jRCT))
- Sponsor: Merck Sharp & Dohme LLC
- Collaborators: Daiichi Sankyo
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 1,000 (estimated)
- Start: 2025-07-21 (actual)
- Primary completion: 2033-07-14 (estimated)
- Primary endpoint: Progression Free Survival (PFS) (Up to approximately 45 months)
- Primary endpoint: Overall Survival (OS) (Up to approximately 85 months)
- Intervention: Patritumab deruxtecan (biological)
- Intervention: Paclitaxel (drug)
- Intervention: Nab-paclitaxel (drug)
- Intervention: Capecitabine (drug)
- Intervention: Pegylated liposomal doxorubicin (drug)
- Intervention: Trastuzumab deruxtecan (biological)
- Intervention: Rescue Medication (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 4 passages in 3 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 70 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 35 sources about other trials or topics are not included.
- These source-specific statements do not establish the prevalence of a view among HCPs or a clinical consensus.
- Some passages in the case discussions and patient-information video were not fully assessed, and discussion without trial names or identifiers may be missing.
- No full protocol or publication reporting HERTHENA-Breast04 outcomes was included in the sources reviewed for this edition; earlier phase 2 evidence and planned assessments must not be read as phase 3 findings.
- Drug-label information was incomplete, including no exact label identified for Patritumab deruxtecan or Nab-paclitaxel. The report does not independently resolve labeled use or eligibility.
- Parallel X and Bluesky content and reposts should not be counted as independent clinical agreement.
- The individual author behind a speaker is not established. The patient-information video's statements are not attributable to a proven named clinician.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-19 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-19 UTC. No changes.

## Offer

- Size: Focused · 27 verified statements · 13 from 4 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (5 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/herthena-breast04-nct07060807
- Agents: POST https://www.erudio.com/api/orders with {"report": "herthena-breast04-nct07060807", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=herthena-breast04-nct07060807

## Cite

Erudio Health. HERTHENA-Breast04 (NCT07060807): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 19, 2026. https://www.erudio.com/reports/herthena-breast04-nct07060807

## Questions

### How much does the HERTHENA-Breast04 report cost?

One edition costs $750 (Focused · 27 verified statements · 13 from 4 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the HERTHENA-Breast04 report cover?

27 statements from 5 sources (1 video, 4 posts), 13 of them from 4 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the HERTHENA-Breast04 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "herthena-breast04-nct07060807" }) previews it and create_order({ "report": "herthena-breast04-nct07060807", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the HERTHENA-Breast04 report?

Edition 1 (version 1.0.0), accepted Nov 19, 2026 UTC; last checked for new commentary Nov 19, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/herthena-breast04-nct07060807.json
- Markdown: https://www.erudio.com/reports/herthena-breast04-nct07060807.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/herthena-breast04-nct07060807/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "herthena-breast04-nct07060807"}`
